Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) | Annals of the Rheumatic Diseases
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study - Lebwohl - 2020 - Journal of the European Academy
NNTs show once-unimaginable psoriasis outcomes now readily attainable | MDedge Rheumatology
PASI-75 Response with Otezla in the Treatment of Moderate to Severe Plaque Psoriasis — Efficacy | Otezla® (apremilast) Healthcare Professional Site
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
PASI-75 and PASI-90 responder rates at weeks 4, 12, 24, and 52.... | Download Scientific Diagram
Health-Related Quality of Life Worsens Disproportionately to Objective Signs of Psoriasis After Withdrawal of Adalimumab Therapy | SpringerLink
Psoriasis treatment cost per PASI 75 in UK, Spain and Portugal
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial - ScienceDirect
Open-label Extension Data: Moderate to Severe Plaque Psoriasis | TREMFYA® (guselkumab) HCP
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period ...
PASI score: Definition and how to calculate
Real-world efficacy of biological agents in moderate-to-severe plaque psoriasis: An analysis of 75 patients in Taiwan | PLOS ONE
Improvement in Psoriasis Symptoms and Physical Functioning with Secukinumab Compared with Placebo and Etanercept in Subjects with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Results of a Subanalysis from the Phase 3 Fixture
PASI 75, 90 and 100 Response Rate. (a) PASI 75. *P = 0.002 week 3; P <... | Download Scientific Diagram
Novartis Dubai Figure 01 - Key Opinions in Medicine
Solved Health State transition PASI 75 maintain PASI 75 PASI | Chegg.com
View Image
Figure 2 | Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis | SpringerLink
New Novartis data shows Cosentyx™ is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients | Novartis
SIMPONI ARIA® Psoriatic Arthritis Efficacy: PASI Response | HCP
